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Michael Boo,1 Karen Ballen,2 Martin Maiers1One-fifth, more than 1000, of all transplants facilitated in 2010 by the National Marrow Donor Program
(NMDP) have employed 1 or 2 umbilical cord blood units as the graft source. As the use of umbilical
cord blood for unrelated allogeneic hematopoietic cell transplantation increases, several issues emerge
that require additional attention and refinement. The U.S. Food and Drug Administration is now far along
in its implementation of regulatory controls for umbilical cord blood. After October 20, 2011, every
unrelated-donor cord blood unit transplanted in the United States must be either licensed or covered under
an FDA-accepted IND. It is incumbent upon transplant physicians to review and understand the implications
of the FDA’s new regulations. In addition, as more transplant programs adopt umbilical cord blood for trans-
plantation, it is important to stay current with the best practices surrounding identification and selection of
the best available units. Cell dose, HLA matching, location of mismatched loci, and the role of noninherited
maternal alleles are all important considerations for unit selection. This complexity in selection of appropri-
ate units raises issues about the desired inventory of umbilical cord blood units. How many units are needed
to meet the needs of all patients who might benefit from cord blood transplantation? Newly developed
simulation models are being utilized by NMDP to answer this question.
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On October 20, 2009, the Center for Biologics
Evaluation and Research (CBER), Food & Drug Ad-
ministration (FDA), issued its Guidance for Industry
(Guidance) [1] addressing the licensing of minimally
manipulated, unrelated allogeneic placental/umbilical
cord blood intended for hematopoietic reconstitution
for specific indications. At the same time it issued
a Draft Guidance (Draft Guidance) [2] for cord blood
units that would be used for the indications addressed
in the Guidance but that would not be licensed or
licensable. Together, these documents provide further
advice to the community concerning how the FDA
intends on regulating these products. This document
reviews these guidances.NationalMarrowDonorProgram,Minneapolis,Minnesota;
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In 1997, the FDAproposed a new regulatory frame-
work for human cellular and tissue-based products,
including hematopoietic stem/progenitor cells [3].
The proposed framework provided a tiered approach
to the regulation of human cellular and tissue-based
products, now referred to as human cells, tissues, and
cellular and tissue-based products (HCT/Ps). The
FDA implemented this approach by promulgating 3
final rules, which comprise 21 CFR Part 1271 [4].
These final rules required registration and listing [5],
established standards for donor eligibility [6], and
applied Current Good Tissue Practice to cord blood
banking [7].Licensing of Cord Blood Units for Allogeneic
Use
This Guidance document provides recommenda-
tions for the submission of a biologics license applica-
tion (BLA) [8] for placental/umbilical cord blood
products that are:
 manipulated minimally; and
 intended for hematopoietic reconstitution in patients
with any of the following diseases;
B hematologic malignancies
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zyme deficiency disorders
- Hurler Syndrome (MPS I)
- Krabbe Disease (Globoid Leukodystrophy)
B X-linked adrenoleukodystropy
B primary immunodeficiency diseases
B bone marrow failure
B beta thalassemia; and
 intended to be used in recipients unrelated to the
donor.
For the purpose of this Guidance, these minimally
manipulated allogeneic products for the above-stated
indications are referred to as hematopoietic progenitor
cells, cord (HPC-C). Manipulated minimally HPC-Cs
that do not meet this definition are not covered by the
Guidance and may require submission of a separate
IND or pursuit of other premarketing application
approval for that product [9].
The Guidance also does not apply to HPC-Cs that
are used for autologous use, or use in first- or second-
degree blood relatives as these are under a different
statute within the Public Health Services Act [10].
The Guidance identifies those regulations that
are applicable to HPC-Cs and include labeling [11],
prescription drug advertising [12], compliance with
Current Good Manufacturing Practice Regulations
[13], and regulations that apply to biological products
generally [14].
The Guidance notes that HPC-C manufacture is
covered by 2 sets of somewhat overlapping regulations.
The Current Good Tissue Practice (cGTP) require-
ments govern manufacture specifically to prevent the
introduction, transmission, or spread of communica-
ble diseases. In addition, because of the licensure and
premarketing approval requirements, cord blood
banks are also subject to Current GoodManufacturing
Practice (cGMP) requirements that apply to pharma-
ceutical companies. cGMP requirements are intended
to ensure the safety, quality, identity, purity, and
potency of the manufactured product. Because of the
broad scope of the regulations, cGMP compliance
subsumes major portions of the cGTP requirements.
That is, compliance with the former is sufficient to
ensure compliance with the overlapping portions of
cGTP.
Issues under the Guidance
The Guidance specifies the indications for which
a licensed cord blood unit is approved. It is assumed
that use of a licensed unit for a nonlicensed indication
will fall within the off label use exception, although
CBER indicates in its Guidance that an IND or other
premarket application review would be appropriate.
 Regulations applicable to a licensed CBB facility in-
clude adherence to good manufacturing processes.
The extent to which the application of theseregulations will require change to current manu-
facturing practices is unknown.
 The Guidance does not specify a date of manufac-
ture for which the license would attach. Banks will
have to work with the CBER to determine whether
pre BLA inventory will qualify as licensed products.
It is expected that this will be addressed inmost cases
through the BLA process.Accessing Unlicensed Cord Blood Units for
Allogeneic Use
As a companion to the Guidance for BLA for
HPC-Cs, CBER also released a Draft Guidance to
cover use of HPC-Cs in instances where a licensed
unit is not available. Specifically, the Draft Guidance
provides for an IND structure to cover the following
circumstances:
 manufactured in non-United States cord blood
establishments, listed in international cord blood
registries, and selected for treatment of a patient in
the United STates;
 manufactured in United States cord blood establish-
ments before a biologic’s license application has
been approved and not shown to meet licensing
criteria (eg, not shown to be comparable to other
licensed HPC-C in inventories);
 prospectively manufactured in theUnited States and
do not meet licensing criteria, but for which there is
no satisfactory alternative. For example, units from
babies whose mothers have positive screening for
Hepatitis B cannot be licensed, but may be valuable
because of their unique HLA phenotypes.
Under the Draft Guidance, units that meet the
qualifications listed above and are used for the treat-
ment of diseases identified in the Guidance would
fall under this IND structure. There are over
500,000 CBUs in the worldwide inventory available
for public use. Most of these units are not expected
to be licensed in the near future. Thus, most current
units will need to be facilitated under an IND for
a number of years. The NMDP is developing an
IND protocol that will facilitate access by transplant
centers to units that fall under the 3 categories. It is en-
visioned that the NMDP protocol will be flexible with
respect to preparative regimens, GVHD prophylaxis,
etc., and focus on collecting outcomes data and signif-
icant adverse events. The NMDP protocol would
allow patients to co-enroll on other clinical trials.
The Draft Guidance responded to comments from
industry over the course of the data collection process
for the BLA that addressed concerns raised regarding
existing inventories and the need to have access to well-
matchedunits in inventories outsideof theUnitedStates.
The Draft Guidance details a number of other
elements of an IND for this purpose. For instance,
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banks that will create an IND tomake their nonlicensed
inventory available to transplant centers, registries that
list and facilitate access to cord blood units whose reg-
istry includes nonlicensed units; and transplant physi-
cians who may seek an IND for purposes of accessing
unlicensed cord blood units for treatment of patients.
In creating the opportunity for multiple sponsors,
it appears that CBER was responding to issues raised
regarding convenience as well as current industry prac-
tice regarding access to cord blood units. In many in-
stances, for example, cord blood banks do not have
separate registries through which they list their own
inventory, but do so under registries such as that
maintained by the National Marrow Donor Program.
Further, by providing for different opportunities for
IND sponsorship, CBER makes it possible for banks
that distribute units directly to transplant centers as
well as transplant centers with active cord blood
programs to create their own INDs.
Sponsors are required to submit safety reports and
annual reports as required by statutes and regulations
governing INDs, to ensure that licensed physicians
are qualified to administer HPC-Cs, provide licensed
physicians with the required information, maintain
an effective IND with respect to investigations, and
maintain adequate drug disposition records.
CBER anticipates that the investigators under the
IND will be physicians who administer HPC-Cs.
Investigators are required to report adverse drug
events to the sponsor, ensure that the informed con-
sent requirements are met, ensure the IRB review of
the HPCs accessed under the IND is obtained, and
maintain accurate case histories and drug disposition
records.
Issues under the IND
 The INDGuidance provides that cord blood banks,
registries, or transplant physicians could be spon-
sors. It is possible that a single unit could fall under
a number of different INDs as where a cord blood
bank holds an IND that lists that cord blood unit
through a registry that has its own IND. Coordina-
tion of data collection under 1 or more INDs will
need to be addressed.
 It is not likely that international registries or cord
blood banks will pursue either a BLA or an IND.
Although there is significant importation of cord
blood units into the United States, no single registry
or bank provides enough products to the United
States to justify the time and expense or compliance
requirements. The NMDP anticipates maintaining
an IND that will include these banks and registries.
 International cord blood banks and registries operate
under practices specific to the countries in which they
are located as well as commonly meet internationalstandards as provided through accrediting bodies
such asNetCord/FACT (Foundation for the Accred-
itation of Cellular Therapy), and AABB. These regis-
tries and accrediting bodies provide a mechanism to
assure that the cord blood banks meet either national
standards or international standards of operations.
How these standards may be used to show qualifica-
tion under the IND is unclear.
 Under the regulations, CBER seeks to have access to
labels used on products that may be imported under
the IND. However, labels are typically in the
language of the country in which the unit has been
collected and stored, and labels have changed over
time as the industry has developed standards for
labeling.
 Products distributed under an IND protocol cannot
be charged for unless the FDA specifically grants
‘‘cost recovery’’ approval [15]. Such approval requires
documentation of all costs of manufacture and distri-
bution, among other things, and prohibits including
certain expenses. Banksmay not have the cost records
required to establish cost recovery rates, and further,
the costs incurred may have changed over time.Summary
With the issuance of the Guidance and Draft
Guidance, a framework for licensing of publicly avail-
able cord blood units for allogeneic use has now
emerged. While the Draft Guidance is yet to be issued
in final form, the industry can now move forward
toward a market with clearer regulation. Although
standards and practices in the cord blood industry
will continue to evolve, licensing and companion
IND guidance will serve to support consistent quality
for banking in the United States while allowing for
appropriate importation and use of existing inventory.BEST PRACTICES AND EMERGING TRENDS
IN CORD BLOOD UNIT SELECTION
Introduction
Only 30% of patients have a matched sibling do-
nor, and therefore the majority of patients who need
an allogeneic transplant will need to find an alternative
stem cell source. Umbilical cord blood (UCB) is a via-
ble stem cell source, particularly for racial and ethnic
minority patients who may have a more difficult time
finding appropriately matched adult unrelated donors.
Over 10,000 UCB have been performed worldwide,
and over 500,000 UCB units have been donated and
are available in public storage banks. We celebrated
the 20th anniversary of the first cord blood transplant
2 years ago, but there is still much to learn about the
appropriate strategy for cord blood unit selection for
unrelated transplants. In this section, we will discuss
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tion for pediatric transplants, and adult single and
double UCB transplants.
Pediatric Transplants
The first successful UCB transplants were per-
formed in children [16-18]. In an early pediatric
experience, Locatelli and others [19] recognized that
the infused nucleated cell dose correlated with survival.
Rubinstein reported that cell dose was directly corre-
lated with the time to myeloid engraftment; therefore,
many pediatric centers accept a minimal cell dose of
2  107 NC/kg but aim for a target dose of 5  107
NC/kg. There does not appear to be any disadvantage
to very high cell doses [20].
The effect of HLA matching has recently been ac-
cepted as an important factor inUCBoutcomes.Gluck-
man reported a higher incidence of graft-versus-host
disease (GVHD) and longer platelet recovery with
both Class I and Class II mismatches [21]. The effect
of HLA mismatch is most important when the cell
dose is low [22]. Eapen et al. [23] has shown an improved
survival for 6/6 matched cord blood units (60% versus
38% for 5/6 or 4/6) for children with acute leukemia.
The Duke group has successfully transplanted
several hundred patients with inherited metabolic dis-
orders. In 1 study of 159 patients, infused (postthaw)
colony-forming units (CFUs) was the graft character-
istic that correlated best with neutrophil and platelet
engraftment [24]. There was no correlation between
storage time and transplant outcomes, to indicate
that the ‘‘freshness’’ of the unit should be considered
in cord blood unit selection [25].
UCB unit viability remains an important determi-
nant of UCB quality. A recent study from the St. Louis
Cord Blood Bank showed concordance among trypan
blue, acridine orange/propidium iodide, and flow
cytometric 7-aminoactinomycin D (7-AAD) viability
testing [26]. ‘‘Global’’ viability of all white blood
cell count (WBC) exhibited temperature variation,
whereas viability of CD341 cells correlated best with
colony-forming cell recovery. An attached segment
to the UCB, which can be thawed at the transplant
center without affecting the integrity of the UCB, en-
sures graft potency and confirmatory HLA testing just
prior to transplantation [27].
Adult Single Cord Unit Transplant
The issues of cord blood selection in adults are
more complex as a higher cell dose per kilogram is
more difficult to achieve. Recent analyses have sug-
gested comparable leukemia free survival probabilities
in adults receiving UCB, 8/8 or 7/8 allele level
matched unrelated PBSC [28]. Barker and colleagues
[29] studied the relationship between cell dose and
HLA match in 1068 patients undergoing cord bloodtransplantation. Both cell dose and HLA match were
independent predictors of transplant-related mortal-
ity. Patients receiving a 6/6 matched CB unit had
improved outcomes, regardless of cell dose. A 4/6
matched UCB with cell dose .5.0  107 NC/kg was
comparable to a 5/6 matched CB unit with cell dose
2.5-5.0  107 NC/kg.
Recently, the presence of HLA antibodies has been
investigated for their potential effect on engraftment
after UCB transplantation [30].
Several UCB banks have maternal DNA stored for
maternal HLA testing [31]. van Rood and colleagues
showed an advantage to selection of units matched at
the noninherited maternal allele. The analysis included
1121 patients transplanted for hematologic malignancy.
A total of 1059 patients received a mismatched UCB
graft; of these patients, 79 patients had a mismatched
antigen identical to a donor noninherited maternal
allele. These patients had comparable results to those
patients receiving a fully matched UCB unit.
Remaining questions are the importance of allele
level matching for Class I and the importance of other
alleles, such asHLAC [32]. These are topics of current
investigation.Double Cord Unit Transplant
UCB unit selection becomes even more compli-
cated for patients undergoing double cord blood trans-
plant. The population in the United States is, on
average, 10 to 15 kg heavier than in Europe and Asia;
therefore, double UCB is more popular in the United
States [33,34]. In addition, preliminary data suggests
that the relapse rate may be lower after double UCB
transplantation [35]. It is not clear if the same princi-
ples of UCB selection for single UCB transplants
apply to double UCB transplants. However, 1 strategy
would be to optimize the HLA match and use 2 CBU
to increase cell dose [29].
Reduced-intensity double UCB transplantation
has become more popular because of a median age of
68 years in patients with acute leukemia, and to
improvements in supportive care that allow these older
patients to be transplanted successfully [36]. The need
for a different cell dose or other selection criteria in re-
duced intensity compared to myeloablative UCB has
not been well studied. Many programs have adopted
a minimum UCB requirement of a 4/6 or better A,
B, DR HLA match between the patient and each
UCB unit and between the 2UCB for bothmyeloabla-
tive and reduced-intensity double UCB transplanta-
tion [33,34,36].
Allele level typing at Class I is not routinely used in
UCB selection, despite significant data in the unre-
lated donor transplant literature supporting optimal
allele level matching. Delaney and colleagues [37]
used allele level typing at Class I and Class II and
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the predominant cord. Allele level matching at HLA B
was associated with improved neutrophil engraftment,
however.
The clinical importance of killer-immunoglobulin
receptor-ligand (KIR-L) mismatching is under investi-
gation, with conflicting results. Willemze et al. [36]
found a survival advantage to KIR-L mismatching in
recipients of myeloablative transplants with acute leuke-
mia. Brunstein and colleagues [38] studied 91 single and
166 double UCB recipients. Brunstein and colleagues
[39] studied 91 single and 166 double UCB recipients.
KIR-Lmismatching had no effect onGVHDor survival
after myeloablative conditioning, but after reduced-
intensity conditioning, KIR-L mismatch between the
patient and the dominant unit resulted in a higher rate
of GVHD, increased transplant related mortality, and
inferior survival. These results suggest that KIR-L mis-
matching should be avoided in reduced-intensity UCB
transplantation. Further investigation will be required,
however, to ascertain the impact, particularly on overall
survival (OS), of KIR-L mismatching in the different
patient populations.
Strategy for Cord Blood Unit Selection
1. All patients should receive a cell dose of.2.5 107
NC/kg. If double UCB each UCB should have cell
dose of .1.5  107 NC/kg.
2. All patients should receive a 4/6 or better A, B, DR
HLAmatchedCBU. If doubleUCB, the units should
also be a 4/6 or better HLA match to each other.
3. If units have an adequate cell dose of .2.5  107
NC/kg, a 6/6 match is preferable, then a 5/6
matched unit.
4. Avoid HLA mismatches at loci in which patients
have preformed HLA antibodies.
5. If maternal typing is available, select mismatch at
the noninherited maternal allele.
6. Still under investigation: HLA C and HLA DQ
matching, KIR matching, and need for allele level
typing at Class I.MODELING THE UTILITYOFACORD BLOOD
UNIT INVENTORY
Given the dual requirements forHLAmatching and
aminimum acceptable cell dose, the challenge ofmodel-
ing the utility of a cord blood unit inventory becomes
quite complex. The model must consider the HLA
composition of the inventory, the HLA repertoire of
the patient population, the nucleated cell content of
stored units and the weight of the searching patients.
To address the HLA matching issue, one must know
the frequency of various HLA haplotypes (eg, A, B, DR
haplotypes for ‘‘6 of 6’’ matching) in the registry and inthe searching patient population. Given the haplotype
frequencies, phenotype frequencies can be computed
fromhaplotype combinations that yield the givenpheno-
type. Tomi and colleagues [40,41] pioneered methods
for estimating haplotype frequencies from HLA
phenotype information. The computational technique,
termed the Estimation Maximization (EM) Algorithm,
essentially says that if a specific set of A, B, and DR
types are seen often in a population of phenotypes, they
are probably on the same chromosome and thus
represent a haplotype. Given the phenotype data from
a large population, the EM algorithm makes it possible
to calculate thousands of haplotype frequencies. Tomi
et al. performed such calculations for adult bone
marrow donors typed by low-resolution serologic
methods and segmented into 4 racial populations.
We have developed methods to extend haplotype
frequency calculations to the high-resolution allele-
level within 21 specific racial and ethnic populations.
For example, we identified 4 populations of Blacks:
African American, African, Caribbean, and South or
Central American. Within the population often re-
ferred to as Asian/Pacific Islander, we found 8 distinct
groups: Chinese, Japanese, Korean, Filipino, Vietnam-
ese, South Asian, Hawaiian/Other Pacific Islander, and
Other Southeast Asian. Our methods have allowed us
to model an adult donor registry at 7-8 of 8-allele
matching stringency and a cord blood unit inventory
with intermediate matching at HLA-A and B and
allele-level matching at DRB1 within and between
each racial/ethnic population. We have also modeled
the impact of a minimum cell dose (2.5  107 NC/kg)
in pediatric and adult patient populations.
Our analysis shows that Caucasians of European
extraction have the highest likelihood of finding a suit-
able adult donor or a suitable cord blood unit. Match-
ing rates are lowest for the Black populations, but
umbilical cord blood ismore likely to provide a suitable
match than the adult donor registry.Summary
The field of umbilical cord blood transplantation
continues to change. A regulatory framework for the
United States will be implemented during 2011. Clin-
ical practices surrounding unit selection have become
more robust. As the clinical knowledge increases, it
helps to refine and improve computational models
that examine the likelihood of a suitable matching
unit and the impact of increasing umbilical cord blood
unit inventories.ACKNOWLEDGMENTS
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